MOMA-341 is being developed as a treatment for cancers with microsatellite instability. Credit: plo / Shutterstock.

US-based biotechnology company MOMA Therapeutics has dosed the first patient in its Phase I clinical trial of MOMA-313, a polymerase theta helicase inhibitor.

The multi-centre, open-label study aims to evaluate MOMA-313’s safety and tolerability in patients with solid tumours.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

MOMA-313 is a highly potent and selective oral polymerase theta helicase inhibitor designed to be used in combination with a PARP inhibitor.

The drug targets patients with specific DNA repair gene alterations, including certain subgroups with prostate, pancreatic and breast cancers.

The trial will assess MOMA-313’s efficacy both as a single agent and in combination with the PARP inhibitor olaparib.

MOMA CEO Asit Parikh said: “We are excited to be progressing two molecules with best-in-class potential toward the benefit of cancer patients in need in such close proximity.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“This progress serves as a testament to the excellence and unwavering commitment of the entire MOMA team.”

In addition to this study, MOMA Therapeutics has identified a development candidate for another lead programme, the Werner helicase inhibitor MOMA-341.

MOMA-341 is being developed as a treatment for cancers with microsatellite instability such as colorectal, gastric and endometrial cancers.

It will be tested both as a monotherapy and in combination with other treatments, including chemotherapy and immunotherapy.

MOMA Therapeutics expects to submit an investigational new drug (IND) application for MOMA-341 to the US Food and Drug Administration (FDA) early next year.

Both MOMA-313 and MOMA-341 were discovered and developed using the KNOMATIC platform, which uses structural insights, advanced hit-finding technologies and computational lead optimisation to expedite the discovery of therapeutics targeting dynamic protein families.

MOMA chief scientific officer Peter Hammerman said: “Advancing two highly potent and selective drug candidates derived from our proprietary KNOMATIC platform toward the clinic is a unique privilege.

“The goal with each candidate is to translate groundbreaking science into life-altering medicine.”